Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor

贝伐单抗 PARP抑制剂 医学 卵巢癌 聚ADP核糖聚合酶 癌症研究 血管生成抑制剂 肿瘤科 化疗 内科学 癌症 奥拉帕尼 联合疗法 单克隆
作者
Hyun‐Woong Cho,Jeong-Yeol Park,Myong Cheol Lim,Byoung-Gie Kim,Seungbong Han,Min Chul Choi,Jae‐Weon Kim,DH Jeong,Hae Seo,Jungmin Choi,E. Pujade-Lauraine,Jung-Yun Lee
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (13): 2537-2545
标识
DOI:10.1158/1078-0432.ccr-25-2916
摘要

PURPOSE: This study aimed to evaluate the efficacy and safety of PARP inhibitor (PARPi) rechallenge combined with bevacizumab as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARPi. PATIENTS AND METHODS: KGOG 3056/NIRVANA-R is a multicenter, single-arm, phase II trial that enrolled 44 patients with platinum-sensitive recurrent ovarian cancer who had received ≥2 prior lines of platinum-based chemotherapy and prior PARPi maintenance. Eligible patients achieving a response to the most recent platinum therapy received daily niraparib and triweekly bevacizumab until disease progression or unacceptable toxicity. The primary endpoint was the 6-month progression-free survival (PFS) rate, analyzed using a Simon two-stage design with adaptive statistical inference. RESULTS: The primary endpoint was met, with 26 of 44 patients (59.1%) remaining progression-free at 6 months. The estimated 6-month PFS rate was 68% [95% confidence interval (CI), 55%-85%], and the median PFS was 11.5 months (95% CI, 7.9-not reached). Subgroup analyses suggested greater benefit in patients with a longer treatment-free interval after the penultimate chemotherapy and in those who achieved a complete response to the most recent chemotherapy. Grade ≥3 treatment-related adverse events occurred in 27.3% of patients, with no treatment-related deaths or new safety signals observed. CONCLUSIONS: This is the first report of PARPi rechallenge with bevacizumab as maintenance therapy in this setting. The combination demonstrated promising efficacy, particularly in patients with favorable platinum responsiveness, and warrants further investigation in biomarker-driven studies. See related commentary by Sachdeva and Tan, p. 2525.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Sunshine完成签到,获得积分10
2秒前
ranran完成签到,获得积分10
2秒前
拉普拉斯妖完成签到,获得积分10
2秒前
2秒前
wawawa关注了科研通微信公众号
2秒前
2秒前
joshua完成签到,获得积分10
3秒前
MuMu完成签到,获得积分10
3秒前
4秒前
juan完成签到 ,获得积分10
4秒前
kuku发布了新的文献求助10
4秒前
大宝宝发布了新的文献求助10
5秒前
5秒前
5秒前
自觉的毛衣完成签到,获得积分20
5秒前
HEGONG发布了新的文献求助10
6秒前
6秒前
kamisama发布了新的文献求助10
6秒前
杨芷昀发布了新的文献求助10
6秒前
7秒前
8秒前
919zm的应助被Avolie采纳,获得10
8秒前
黑米粥发布了新的文献求助200
8秒前
2293889发布了新的文献求助10
8秒前
新八完成签到,获得积分10
9秒前
9秒前
dxftx发布了新的文献求助10
9秒前
11秒前
完美世界的应助被thr采纳,获得10
12秒前
gong关注了科研通微信公众号
12秒前
壁虎君发布了新的文献求助10
14秒前
无花果的应助被小朱采纳,获得10
14秒前
14秒前
qi发布了新的文献求助10
15秒前
zz发布了新的文献求助10
15秒前
15秒前
发发发完成签到 ,获得积分10
16秒前
SciGPT的应助被JiangXW采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187572
求助须知:如何正确求助?哪些是违规求助? 9575676
关于积分的说明 21842241
捐赠科研通 7785368
什么是DOI,文献DOI怎么找? 3435022
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481917